ASX:TLX Telix Pharmaceuticals (TLX) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free TLX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume746,789 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Telix Pharmaceuticals alerts: Email Address Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Telix Pharmaceuticals Stock (ASX:TLX)Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one TLX Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comWorld First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in SpainMarch 12, 2024 | wsj.comTelix Pharmaceuticals Ltd.March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 4, 2024 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production PlatformFebruary 22, 2024 | msn.comInaugural profit overlooked as R&D spending soars at Telix PharmaceuticalsFebruary 22, 2024 | finance.yahoo.comTelix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage PipelineFebruary 8, 2024 | finanznachrichten.deQSAM Biosciences Inc.: QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix PharmaceuticalsFebruary 7, 2024 | finance.yahoo.comTelix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting PlatformMarch 28, 2024 | Porter & Company (Ad)Only a fool would buy Nvidia today… Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.February 7, 2024 | finance.yahoo.comQSAM Biosciences Signs Definitive Agreement to be Acquired by Telix PharmaceuticalsFebruary 2, 2024 | fool.com.au2 top ASX growth shares to buy right now and hold for the long termJanuary 22, 2024 | finance.yahoo.comTelix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)January 4, 2024 | finance.yahoo.comTelix Announces Planned Registered Public Offering and Listing in the United StatesJanuary 4, 2024 | finance.yahoo.comUPDATE 2-Australia's Telix Pharmaceuticals jumps on potential US listingJanuary 4, 2024 | ca.finance.yahoo.comAustralia's Telix Pharmaceuticals jumps on potential US listingJanuary 3, 2024 | finance.yahoo.comTelix to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix) for Imaging of Kidney CancerDecember 18, 2023 | finance.yahoo.comTelix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney CancerDecember 4, 2023 | finance.yahoo.comFirst Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging AgentNovember 29, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCSNovember 29, 2023 | finance.yahoo.comPhase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCSNovember 22, 2023 | fool.com.auCould buying these ASX shares at $9 now be like investing in Tesla in 2010?November 14, 2023 | finance.yahoo.comQSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option FeeNovember 13, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®November 13, 2023 | finance.yahoo.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryNovember 13, 2023 | finance.yahoo.comTelix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology SurgeryNovember 8, 2023 | finance.yahoo.comTelix to Present at Jefferies London Healthcare Conference 2023See More Headlines Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:TLX CUSIPN/A CIKN/A Webwww.telixpharma.com Phone61 4 4914 8448FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.02 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.21 million Net Margins1.04% Pretax MarginN/A Return on Equity4.55% Return on Assets9.92% Debt Debt-to-Equity Ratio11.72 Current Ratio1.43 Quick Ratio3.00 Sales & Book Value Annual Sales$502.55 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.35 Book ValueA$0.46 per share Price / BookN/AMiscellaneous Outstanding Shares323,980,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.35 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Darren Smith B.Bus. (Age 59)FCPA, M.B.A., Group Chief Financial Officer Comp: $571.17kDr. Andreas Kluge M.D.Ph.D., Chief Medical Advisor & Non-Executive DirectorMr. Richard Valeix M.B.A.Group Chief Commercial OfficerDr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.Group General CounselThomas FrommVice President of SalesMr. Ted StephensVice President of MarketingMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersChristian BehrenbruchSold 153,298 sharesTotal: $1.69 M ($11.00/share)Christian BehrenbruchSold 120,268 sharesTotal: $356,714.89 ($2.97/share) TLX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Telix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS). This page (ASX:TLX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.